This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
by Sundeep Ganoria
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
by Zacks Equity Research
GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
by Zacks Equity Research
The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
by Kinjel Shah
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
by Zacks Equity Research
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
by Sundeep Ganoria
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Pfizer (PFE) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
by Zacks Equity Research
Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
by Zacks Equity Research
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
by Zacks Equity Research
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
by Zacks Equity Research
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet
by Zacks Equity Research
Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet are included in this Analyst Blog.
Top Stock Reports for Amazon.com, Visa & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE).
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
by Kinjel Shah
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
Here's Why Pfizer (PFE) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Company News for May 2, 2024
by Zacks Equity Research
Companies In The News Are: CVS, PFE, PPL, ADP.
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
by Zacks Equity Research
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?